BioXcel Therapeutics (BTAI) Other Non-Current Assets (2018 - 2025)
BioXcel Therapeutics (BTAI) posted quarterly Other Non-Current Assets of $87000.0 for Q1 2025, little changed year-over-year from $87000.0 in Q1 2024, and little changed quarter-over-quarter from $87000.0 in Q4 2024.
BioXcel Therapeutics (BTAI) Other Non-Current Assets (2018 - 2025) Analysis & Trends
BioXcel Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $87000.0 for Q1 2025.
- In Q1 2025, Other Non-Current Assets changed 0.0% year-over-year to $87000.0; the TTM figure through Mar 2025 stood at $87000.0 (changed 0.0% YoY), while the FY2024 annual figure was $87000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2025 stood at $87000.0, roughly flat from $87000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.8 million in Q3 2021, with the low at $86000.0 in Q4 2021.
- The 5-year median for Other Non-Current Assets is $87000.0 (2023), against an average of $556764.7.
- The sharpest annual moves came in 2021 and 2023: Other Non-Current Assets jumped 3096.08% in 2021, then slumped 90.59% in 2023.
- BioXcel Therapeutics' Other Non-Current Assets stood at $86000.0 in 2021, then soared by 975.58% to $925000.0 in 2022, then plunged by 90.59% to $87000.0 in 2023, then changed by 0.0% to $87000.0 in 2024, then changed by 0.0% to $87000.0 in 2025.
- Business Quant data shows BTAI's Other Non-Current Assets at $87000.0 in Q1 2025, $87000.0 in Q4 2024, and $87000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 87,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Mar 31, 2023 | 925,000.00 |
| Dec 31, 2022 | 925,000.00 |
| Sep 30, 2022 | 925,000.00 |
| Jun 30, 2022 | 925,000.00 |
| Mar 31, 2022 | 965,000.00 |
| Dec 31, 2021 | 86,000.00 |
| Sep 30, 2021 | 1.76 Mn |
| Jun 30, 2021 | 1.63 Mn |
| Mar 31, 2021 | 633,000.00 |
| Dec 31, 2020 | 87,000.00 |
| Sep 30, 2020 | 86,000.00 |
| Jun 30, 2020 | 51,000.00 |